Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Infigratinib 0.016 mg/kg
BridgeBio Oncology Therapeutics
Achondroplasia
1 trial -
Infigratinib is provided as a single dose of minitablets for oral administration
BridgeBio Oncology Therapeutics
Achondroplasia
1 trial -
Intravitreal Aflibercept Injection
Regeneron UK Limited
Central Serous Chorioretinopathy
1 trial -
Iparomlimab and Tuvonralimab Injection (QL1706)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholangiocarcinoma
1 trial -
LUM001
Mirum Pharmaceuticals International B.V.
Primary Sclerosing Cholangitis (PSC)
1 trial -
LUM001 (Maralixibat)
Mirum Pharmaceuticals International B.V.
Progressive Familial Intrahepatic Cholestasis (PFIC)
1 trial -
Lenalidomide combined with G-CHOP (LO CHOP)
The First People's Hospital of Lianyungang
DLBCL - Diffuse Large B Cell Lymphoma
1 trial -
Liposorber LA-15 System
Hospital Authority, Hong Kong
Cholesterol Embolism
1 trial -
Lumevoq
GenSight Biologics S.A.
Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
1 trial -
Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN
Shanghai Reinovax Biologics Co.,LTD
Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoiceΒ© test)
1 trial -
MB07811
LIGAND PHARMACEUTICALS INC
Hypercholesterolemia
1 trial -
MD-0727
IRONWOOD PHARMACEUTICALS INC
Hypercholesterolemia
1 trial -
MGL-3196 (resmetirom)
Madrigal Pharmaceuticals EU Limited
Heterozygous Familial Hypercholesterolemia
1 trial -
ML-007C-MA
MapLight Therapeutics
Psychosis Associated With Alzheimer's Disease
2 trials -
MSC
The Children's Hospital of Zhejiang University School of Medicine
BPD - Bronchopulmonary Dysplasia
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Cholestatic Liver Disease
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Progressive Familial Intrahepatic Cholestasis
1 trial -
Maralixibat
Mirum Pharmaceuticals International B.V.
Intrahepatic Cholestasis of Pregnancy
1 trial -
Mavodelpar
OnKure Therapeutics
Primary Mitochondrial Myopathy
1 trial -
Melphalan flufenamide (Melflufen)
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma
1 trial -
Miricorilant
CORCEPT THERAPEUTICS INC
Antipsychotic-induced Weight Gain (AIWG)
1 trial -
Miricorlilant
CORCEPT THERAPEUTICS INC
Antipsychotic-induced Weight Gain (AIWG)
1 trial -
NEO-201 in combination with pembrolizumab
Chongqing Precision Biotech Co., Ltd
Non Small Cell Lung Cancer
1 trial -
NPC-1C/NEO-102
Chongqing Precision Biotech Co., Ltd
Metastatic Pancreatic Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources